+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
FEMALE
ID06403618

Study of the PreCursor-M Test in Women Diagnosed With Cervical Intraepithelial Neoplasia Grade 2 CIN2

Led by European Institute of Oncology · Updated on 2025-05-23

100

Participants Needed

2

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying women diagnosed with Cervical Intraepithelial Neoplasia Grade 2 CIN2 to assess the accuracy and sensitivity of the PreCursor-M assay. This test examines methylation levels of specific host cell genes associated with cervical cancer risk. The study aims to evaluate the clinical course of CIN2 over two years, including an assessment at six months, to better understand disease progression or regression. After enrollment, participants are divided into two groups one follows an active surveillance or watchful waiting approach, while the other receives immediate surgical treatment as per clinical practice. The study evaluates clinical outcomes such as regression, persistence, or progression of CIN2 in the surveillance group, and histological changes and recurrence rates in the treatment group over two years. Participants will undergo baseline testing with the PreCursor-M assay and be monitored through clinical evaluations at six months and two years. Researchers will assess gene methylation and clinical disease status, measuring outcomes like regression or progression of CIN2 and overall test accuracy. Participants provide informed consent and must meet eligibility criteria before joining.

CONDITIONS

Brief Title

Evaluation of the PreCursor-M+® in CIN2

Research Team

A

Anna Daniela Iacobone

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here